Send to

Choose Destination
Neurol Res. 1997 Apr;19(2):145-52.

Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes.

Author information

Virginia Commonwealth University, Medical College of Virginia, Richmond 23298-0631, USA.


Malignant glioma remains one disease for which there is no curative therapy. Clearly there is a need to explore new and innovative approaches for their treatment. In this report, we review our preclinical trial of a new adoptive immunotherapy protocol using cytotoxic T lymphocytes (CTL) which had been sensitized to glioma in vivo and then activated and their number expanded ex vivo using compounds which enhance signal transduction. These glioma-sensitized lymphocytes, when introduced systemically into rats with either an intracerebral or intradermal glioma, eradicated or slowed the progression of their tumor. These results indicate for the first time that a reproducible and sustained eradication of a malignant glioma could be achieved by the adoptive transfer of tumor-sensitized, ex vivo expanded CTL. A Phase I clinical trial is now underway to test the safety and potential efficacy of this immunotherapy in patients with recurrent malignant glioma.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center